<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6889">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017235</url>
  </required_header>
  <id_info>
    <org_study_id>000253</org_study_id>
    <nct_id>NCT03017235</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy</brief_title>
  <official_title>A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution Versus Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Powder for Oral Solution (PREPOPIK®) for Colon Cleansing in Preparation for Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the Sodium Picosulfate, Magnesium Oxide and
      Anhydrous Citric Acid Oral Solution with PREPOPIK® for colon cleansing in adult subjects
      undergoing colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects classified as a responder defined by &quot;excellent&quot; or &quot;good&quot;</measure>
    <time_frame>At day of colonoscopy</time_frame>
    <description>Measured by the Modified Aronchick scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects classified as a responder defined by a score ≥2 in the right segment of the colon</measure>
    <time_frame>At day of colonoscopy</time_frame>
    <description>Measured by the Boston Bowel Preparation Scale (BBPS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects classified as a responder defined by a score ≥2 in the transverse segment of the colon</measure>
    <time_frame>At day of colonoscopy</time_frame>
    <description>Measured by the BBPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects classified as a responder defined by a score ≥2 in the left segment of the colon</measure>
    <time_frame>At day of colonoscopy</time_frame>
    <description>Measured by the BBPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of each category on the Subject Tolerability Questionnaire</measure>
    <time_frame>At day of colonoscopy</time_frame>
    <description>Measured by the Mayo Clinic Bowel Prep Tolerability Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events(AEs)</measure>
    <time_frame>From baseline (screening) up to day 28 after colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>From baseline (screening) up to day 28 after colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in electrocardiogram (ECG)</measure>
    <time_frame>From baseline (screening) up to day 28 after colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in laboratory values</measure>
    <time_frame>From baseline (screening) up to day 28 after colonoscopy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>NaP/MC Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREPOPIK®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution</intervention_name>
    <arm_group_label>NaP/MC Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder</intervention_name>
    <arm_group_label>PREPOPIK®</arm_group_label>
    <other_name>PREPOPIK®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female subjects aged 18 to 80 years, inclusive, being scheduled
             to undergo elective colonoscopy

          -  Females of childbearing potential must agree to use an adequate contraception during
             the course of the trial. Accepted forms of contraception are: i.e., implants,
             injectables, hormonal intrauterine device, combined hormonal contraceptives, sexual
             abstinence, and vasectomized sexual partner. Sterilized or postmenopausal women may
             also participate. Women must have a negative serum pregnancy test result at screening
             and a negative urine pregnancy test result at randomization

          -  An average of at least 3 spontaneous bowel movements per week for one month prior to
             the colonoscopy

        Exclusion Criteria:

          -  Known or suspected gastrointestinal obstruction, perforation, ileus, or gastric
             retention

          -  Acute intestinal or gastric ulceration

          -  Severe acute inflammatory bowel disease (IBD), toxic colitis, or toxic megacolon

          -  Undergoing colonoscopy for foreign body removal or decompression

          -  Reduced level of consciousness or inability to swallow without aspiration

          -  Any prior colorectal surgery, excluding appendectomy, hemorrhoid surgery, or prior
             endoscopic procedures

          -  Upper gastrointestinal surgery (gastrectomy, gastric banding, gastric by-pass)

          -  Uncontrolled angina and/or myocardial infarction (MI) within last three months,
             congestive heart failure (CHF), uncontrolled hypertension, or ascites

          -  Severely reduced renal function (&lt;30 mL/min/1.73 m2)

          -  Pregnant or lactating women

          -  Any clinically relevant abnormal findings in medical history, physical examination,
             vital signs, ECG, clinical chemistry, hematology, coagulation, or urinalysis at
             Screening Visit 1

          -  Rhabdomyolysis

          -  Chronic nausea and vomiting

          -  Hypermagnesemia

          -  Undergoing treatment with Lithium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Gastroenterology Medical Group</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GW Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Group</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Long Island Gastrointestinal Research Group LLC</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists, PA</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hillmont GI</name>
      <address>
        <city>Flourtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward, Inc.</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 16, 2017</lastchanged_date>
  <firstreceived_date>January 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
